ÂÜÀòÂÒÂ×

Emma Reeve served as Senior Vice President and Chief Financial Officer of Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from October 2017 to July 2021, and as Treasurer from December 2017 to July 2021. Prior to joining Constellation Pharmaceuticals, Ms. Reeve served as Corporate Controller of PAREXEL International, a biopharmaceutical services company and contract research organization, from September 2014 to October 2017, and as Interim Chief Financial Officer and Corporate Controller of PAREXEL from July 2016 to May 2017, where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Ms. Reeve served as Head of Finance and Administration at Novartis Pharma Schweiz, a pharmaceutical company, from May 2012 to August 2014, and as Vice President, Global Head Business Planning and Analysis for Novartis Vaccines and Diagnostics, a division of Novartis, from January 2008 to April 2012. She served as Chief Financial Officer of Inotek Pharmaceuticals Inc., a development-stage biotechnology company, from 2006 to 2007. Ms. Reeve was Senior Director of Research Operations at Merck Research Laboratories from 2004 to 2006. Prior to that, she served as Chief Financial Officer of Aton Pharma, Inc., a development-stage biotechnology company, from 2002 to 2004. Ms. Reeve was at Bristol-Myers Squibb Company, a global biopharmaceuticals company, from 1994 to 2002.

Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.